Carly Newton: Closing the Gap in Sickle Cell Disease Readmissions
Carly Newton, Sr Manager of Apheresis Clinical Marketing at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“1 in 3 adults with sickle cell disease are back in the hospital within 30 days of discharge. For some young adults, it’s closer to 40%.
Behind every one of those readmissions is another crisis, more missed work or school, more strain on a family.
The data is consistent: transfusion therapy, especially automated red blood cell exchange (aRBCX), lowers that risk, even for the sickest patients. Yet fewer than 3% of SCD patients access RBCX each year, despite most having the access and prescriber support to get it.
This September, for National Sickle Cell Awareness Month, I’m breaking down why that gap exists and what closing it could mean for the people living this every day.
Read the full article on my Substack.”
Stay updated withΒ Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?